118 related articles for article (PubMed ID: 11062366)
1. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
[TBL] [Abstract][Full Text] [Related]
2. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
3. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
4. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
6. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Yamanaka K; Muramaki M; Kurahashi T; Gleave M; Hara I
Oncol Rep; 2005 Nov; 14(5):1371-5. PubMed ID: 16211311
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Debruyne FM; Witjes WP
Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
[TBL] [Abstract][Full Text] [Related]
9. [What is the best strategy of hormonal therapy in the treatment of locally advanced prostate cancer?].
Ehara H; Nakano M; Deguchi T
Hinyokika Kiyo; 2006 Jun; 52(6):473-7. PubMed ID: 16848361
[TBL] [Abstract][Full Text] [Related]
10. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological significance of neoadjuvant hormonal therapy prior to radical prostatectomy: whole section analysis].
Uemura H; Cho M; Hirao Y; Konishi N
Hinyokika Kiyo; 2002 Nov; 48(11):719-23. PubMed ID: 12512148
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?
Rubin MA; Mucci NR; Manley S; Sanda M; Cushenberry E; Strawderman M; Montie JE; Bassily NH
J Urol; 2001 Jan; 165(1):114-8. PubMed ID: 11125378
[TBL] [Abstract][Full Text] [Related]
14. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
Civantos F
Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
[TBL] [Abstract][Full Text] [Related]
15. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
Stone NN; Stock RG; Unger P
Mol Urol; 2000; 4(3):163-8;discussion 169-70. PubMed ID: 11062370
[TBL] [Abstract][Full Text] [Related]
16. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
17. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
18. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.
Poulos CK; Daggy JK; Cheng L
Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
20. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
